Register Login

Abiopharma

  • Home
  • About
  • Newsroom
    • News
    • Company List
  • Events
  • Automated Tools
  • Contact

News list

Smart for Life, Inc. (SMFL)

  • Business News
  • Jan. 16, 2026, 21:58 UTC
  • 3
  • 1 comments

How Taila Moore McKelvy Turned Inspiration and Tenacity Into an Industrial Engineering Career

Market reaction Comment Full text

Lifecore Biomedical (LFCR)

  • Business News
  • Jan. 16, 2026, 21:45 UTC
  • 3
  • 1 comments

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market reaction Comment Full text

Coherent Inc (COHR)

  • Business News
  • Jan. 16, 2026, 21:10 UTC
  • 3
  • 1 comments

Coherent Introduces Germanium-Free Electro-Optic Modulator for High-Speed CO2 Laser Via Drilling

Market reaction Comment Full text

Savara Inc. (SVRA)

  • Business News
  • Jan. 16, 2026, 21:05 UTC
  • 4
  • 1 comments

Savara Inc. - Savara Announces New Employment Inducement Grant

Market reaction Comment Full text

Sensient Technologies Corporation (SXT)

  • Business News
  • Jan. 16, 2026, 21:05 UTC
  • 3
  • 1 comments

Sensient Technologies Corporation - Sensient Declares Dividend

Market reaction Comment Full text

Context Therapeutics Inc. (CNTX)

  • Business News
  • Jan. 16, 2026, 21:05 UTC
  • 3
  • 1 comments

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market reaction Comment Full text

Coherent Inc (COHR)

  • Business News
  • Jan. 16, 2026, 21:05 UTC
  • 6
  • 1 comments

Coherent Launches AxioView™ Imaging Fiber Assemblies for OCT and Multimodal Medical Catheters

Market reaction Comment Full text

Xenon Pharmaceuticals Inc (XENE)

  • Business News
  • Jan. 16, 2026, 21:05 UTC
  • 3
  • 1 comments

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market reaction Comment Full text

Corvus Pharmaceuticals Inc (CRVS)

  • Business News
  • Jan. 16, 2026, 21:01 UTC
  • 6
  • 1 comments

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Market reaction Comment Full text

Exact Sciences Corporation (EXAS)

  • Business News
  • Jan. 16, 2026, 20:42 UTC
  • 5
  • 1 comments

SC 13G/A (Amended Statement of Ownership) SEC Filing

Market reaction Comment Full text
  • Previous
  • 32
  • 33
  • 34
  • 35
  • 36
  • Next

Search

News categories

  • Technical Exchange News(10847)
  • Event(2204)
  • SEC News(187830)
  • FDA Approval(10304)
  • Company Report(721)
  • Business News(124259)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin